B7-H3, a type I transmembrane protein consisting of 316 amino acids [27], is markedly upregulated in diverse malignancies, including MM, while its expression remains minimal in normal tissues [28, 29], thereby rendering it a promising therapeutic target [30]. This evidence concerns the gene CD276 and Miyoshi myopathy.